PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma.

about

PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma.

Item

http://www.wikidata.org/entity/Q41550899

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma.

@en

type

Item

label

PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma.

@en

prefLabel

PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma.

@en

P1476

PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma.

@en

P2093

Ekaterina S Jordanova

http://www.w3.org/2001/XMLSchema#string

Els M E Verdegaal

http://www.w3.org/2001/XMLSchema#string

Jinfeng Cao

http://www.w3.org/2001/XMLSchema#string

Kate E Richards

http://www.w3.org/2001/XMLSchema#string

Marina Marinkovic

http://www.w3.org/2001/XMLSchema#string

Martine J Jager

http://www.w3.org/2001/XMLSchema#string

Niels J Brouwer

http://www.w3.org/2001/XMLSchema#string

Sjoerd van Duinen

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

PD-L1 is an independent prognostic predictor in gastric cancer of Western patients.

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma

The future of immune checkpoint therapy

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

P304

54722-54734

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.18039

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Daan P Hurkmans

P577

2017-05-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28903377

http://www.w3.org/2001/XMLSchema#string

P932

5589616

http://www.w3.org/2001/XMLSchema#string